Sanofi to Acquire Blueprint Medicines for ~$9.5B

Shots: Sanofi to acquire Blueprint Medicines, expanding its rare immunological disease portfolio As per the deal, Blueprint shareholders will receive $129/share in cash (~$9.1B equity value) & one non-tradeable CVR of $2 & $4 per share upon achievement of development & regulatory milestones, respectively, for BLU-808, totaling the deal value up to $9.5B on a…

ByRidhi RastogiJune 2, 2025

News

VantAI and Blueprint Medicines Expands License Agreement to Advance Induced Proximity Drug Discovery

Shots: VantAI and Blueprint Medicines have expanded their 2022 collaboration, adding new drug target programs to develop therapies for critical medical needs As per the expansion, VantAI will receive up to $1.67B in total including ~$270M R&D and regulatory milestones, and $1.4B commercial milestones across four joint target programs, along with tiered mid-single-digit sales based…

ByDipanshu DixitMay 21, 2025

EXCLUSIVE

Exclusive: Kenneth Sake from Blueprint Medicines in an Enlightening Conversation with PharmaShots

Highlights: Systemic mastocytosis (SM) is a rare disease caused by the abnormal accumulation of mast cells – a key part of the body’s immune system People with SM face potentially debilitating symptoms, such as skin lesions, diarrhoea, bone pain, fatigue and anaphylaxis, which can present challenges across various aspects of patients’ lives For more than…

BySaurabh ChaubeyMarch 12, 2025

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in December 2023

Shots: The EMA approved 3 BLA while 4 New Chemical Entities in December 2023, leading to treatments for patients and advances in the healthcare industry In December 2023, the major highlighted drugs were Jempreli to treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer and Zilbrysq for the treatment of Generalized Myasthenia Gravis PharmaShots has compiled a list of a…

BySaurabh ChaubeyJanuary 23, 2024

EXCLUSIVE

Insights from Coralie Gressier-Sayag on Avapritinib Efficacy Data Presented at EHA 2023

Shots: Coralie started by giving a brief introduction about Systemic Mastocytosis (SM), a rare disease. She told us that in Europe, approximately 40,000 people live with SM, with 80-90% living with Indolent SM and the rest with Advanced SM She then gave an overview of the P-II PATHFINDER study evaluating avapritinib. The study's 2-year follow-up…

BySenior EditorAugust 30, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in May 2023

Shots: The US FDA approved 15 NDAs and 3 BLA in May 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 54 novel products in 2023 In May 2023, the major highlights drugs were, Ayvakit approval for Indolent Systemic Mastocytosis, Rinvoq for Active Crohn's Disease PharmaShots has…

BySenior EditorJune 21, 2023

VIEWPOINTS

Nicolas Paquette-Lamontagne, VP, Medical Affairs at Blueprint Medicines Shares his Views on Clinical Data of Ayvakit for Patients with Systemic Mastocytosis

Shots: Nicolas discussed about Systemic Mastocytosis as a disease and highlighted its epidemiology & other details. He also spoke about the clinical data of avapritinib presented at the ASH’22 Annual Meeting Nicolas also shared the key findings from the PATHFINDER and EXPLORER trial evaluating avapritinib and the rationale behind conducting two different trials This interview…

BySenior EditorFebruary 13, 2023

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2022

The third quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include CVS Health acquired Signify Health for ~$8B, Amgen acquired Chemocentryx for ~$4B The third quarter of the year also showcases multiple approvals of the therapies which include Incyte's Opzelura US FDA's approval for Vitiligo,…

BySenior EditorSeptember 29, 2022

INSIGHTS+

Insights+: The US FDA New Drug Approvals in December 2019 and January 2020

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 48 new products so far in 2019 However, there is a significant increase in multiple diseases while the new approvals are helping and advancing the changes to understand, diagnose and treat the diseases Our team…

BySenior EditorFebruary 21, 2020

Sanofi to Acquire Blueprint Medicines for ~$9.5B

VantAI and Blueprint Medicines Expands License Agreement to Advance Induced Proximity Drug Discovery

Exclusive: Kenneth Sake from Blueprint Medicines in an Enlightening Conversation with PharmaShots

Insights+: EMA Marketing Authorization of New Drugs in December 2023

Insights from Coralie Gressier-Sayag on Avapritinib Efficacy Data Presented at EHA 2023

Insights+: The US FDA New Drug Approvals in May 2023

Nicolas Paquette-Lamontagne, VP, Medical Affairs at Blueprint Medicines Shares his Views on Clinical Data of Ayvakit for Patients with Systemic Mastocytosis

PharmaShots’ Key Highlights of Third Quarter 2022

Insights+: The US FDA New Drug Approvals in December 2019 and January 2020

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter